Between Dec News Today

1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Synovial sarcoma and myxoid round cell liposarcoma are rare, chemo-refractory malignancies with a poor prognosis once metastasized. Current treatment regimens are limited, and a

1. Patients in the KarXT (xanomeline–trospium) group reported a significant reduction in Positive and Negative Syndrome Scale (PANSS) score compared to those in the placebo group. 2. Majority of adverse events were mild-to-moderate, with no treatment-related fatalities or increase in extrapyramidal motor symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Current antipsychotic therapies for schizophrenia

December 8, 2023 2:03 pm Between Dec 6 and Dec 7 2023 an entity connected...

1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group underwent more procedures and surgeries compared to those in the false-positive group. Evidence Rating Level: 2 (Good) Study Rundown: Cancer is a leading cause of death worldwide with nearly two million new cases expected to be diagnosed

1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group underwent more procedures and surgeries compared to those in the false-positive group. Evidence Rating Level: 2 (Good) Study Rundown: Cancer is a leading cause of death worldwide with nearly two million new cases expected to

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in serious adverse events between the baricitinib and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely

Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week 36. Complete remission of proteinuria was significantly higher in the sparsentan group. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is the most common cause of primary glomerulonephritis worldwide. Although renin-angiotensin blockers (ARBs), such as irbesartan,

1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both children

1. Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week 36. 2. Complete remission of proteinuria was significantly higher in the sparsentan group. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is the most common cause of primary glomerulonephritis worldwide. Although renin-angiotensin blockers (ARBs),

1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both